Renal Anemia
29
1
2
20
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 29 trials
100.0%
+13.5% vs benchmark
45%
13 trials in Phase 3/4
10%
2 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (29)
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients
A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD
Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.
The Association Between the Distributions MCH and RBC, and Mortality in Hemodialysis Patients
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents